This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tivicay/Epivir

GlaxoSmithKline plc

Drug Names(s): Tivicay/Epivir FDC, Tivicay + Epivir, Dolutegravir + Lamivudine, DTG + 3TC

Description: ViiV Healthcare (GlaxoSmithKline) is developing a single-tablet combining Tivicay (dolutegravir) and Epivir (lamivudine), for the treatment of human immunodeficiency virus (HIV-1) infections.

Deal Structure: Shionogi and ViiV Healthcare
In December 2015, Shionogi announced that a fixed dose combination tablet of dolutegravir and lamivudine for the treatment of nave and suppressed HIV patients has been out-licensed to ViiV Healthcare.

Partners: Shionogi & Co. Ltd.


Tivicay/Epivir News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug